Clinical trials: Endometrial Cancer Stage I
Cancer
Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of aminocamptothecin in treating patients with advanced…
- Trial name
- NCT00003548
- Testing
- aminocamptothecin colloidal dispersion
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- NYU Langone Health
Endometrial Cancer, Sarcoma
Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether receiving radiation therapy or no further therapy after surgery is more effective for cancer of the uterus.
- Trial name
- NCT00002459
- Testing
- radiation therapy
- Where
- 28 sites in Belgium, Canada and 8 more
- Volunteers
- 224 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
This phase I trial is studying the side effects and best dose of combination chemotherapy when given with radiation therapy in treating patients with stage III or stage IV endometrial cancer.
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer
- Trial name
- NCT00005840
- Testing
- Paclitaxel, Cisplatin, Radiation Therapy
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Gynecologic Oncology Group
Endometrial Carcinoma, Endometrial Carcinoma Stage III
GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial Cancer
GYNORYLAQ-VLINIVAL is an Early Phase I, non-randomized, single-arm, open-label clinical trial enrolling 40 patients with high-risk or recurrent endometrial carcinoma.
- Trial name
- GYNORYLAQ™ (NCT07316361)
- Testing
- • Biological: GYNORYLAQ-TM Personalized Neoantigenic Peptide Vaccine
- Where
- Greece
- Volunteers
- 40 people
- Sponsor
- Biogenea Pharmaceuticals Ltd.
Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
- Conditions
- Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer
- Trial name
- NCT05902988
- Testing
- VLS-1488
- Where
- 14 sites in United States
- Volunteers
- 200 people
- Sponsor
- Volastra Therapeutics, Inc.
Advanced Breast Carcinoma, Advanced Endometrial Carcinoma
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
This phase Ib trial tests the safety, side effects, and best dose of tumor treating fields therapy in combination with either cabozantinib or nab-paclitaxel and atezolizumab in treating patients with solid tumors involving the…
- Conditions
- Advanced Breast Carcinoma, Advanced Endometrial Carcinoma, Advanced Fallopian Tube Carcinoma, Advanced Hepatocellular Carcinoma
- Trial name
- NCT05092373
- Testing
- Atezolizumab, Cabozantinib S-malate, Nab-paclitaxel
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- M.D. Anderson Cancer Center
Endometrial Cancer
Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer
Background: Endometrial cancer is a prevalent gynecological malignancy, with a significant number of cases diagnosed at an advanced stage or recurring following initial treatment.
- Trial name
- LiDer (NCT06385548)
- Testing
- Lurbinectedin, Dostarlimab
- Sponsor
- Vall d'Hebron Institute of Oncology
Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vinorelbine ditartrate, work in different ways to stop the growth of tumor…
- Conditions
- Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma, Male Breast Cancer, Malignant Paraganglioma
- Trial name
- NCT01155258
- Testing
- temsirolimus, vinorelbine ditartrate
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Southern California
Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
This phase III trial compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial…
- Trial name
- NCT05646316
- Testing
- Biospecimen Collection, Diagnostic Imaging Testing, Excisional Biopsy
- Where
- 60 sites in United States, South Korea
- Volunteers
- 428 people
- Sponsor
- NRG Oncology
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma
Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
This phase II trial is studying how well medroxyprogesterone works in treating patients with endometrioid adenocarcinoma (cancer) of the uterine corpus (the body of the uterus, not including the cervix).
- Conditions
- Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation, Recurrent Uterine Corpus Carcinoma
- Trial name
- NCT00064025
- Testing
- Laboratory Biomarker Analysis, Medroxyprogesterone, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Gynecologic Oncology Group
Endometrial Neoplasm Malignant Stage I
Megestrol Acetate Plus LNG-IUS in Young Women With Early Endometrial Cancer
To see if megestrol acetate plus Levonorgestrel-releasing intrauterine system (LNG-IUS) will not be inferior to returning the endometrial tissue to a normal state than megestrol acetate alone in patients with early endometrial…
- Trial name
- NCT03241914
- Testing
- Megestrol Acetate, Levonorgestrel-releasing Intrauterine System(LNG-IUS)
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Fudan University
Cancer
Virtual Trial to Compare Two Digital Therapeutics as Interventions for Physical and Mental Health in People With Cancer
This is a 2-arm randomized controlled study comparing how effective two therapeutic digital software devices are at improving anxiety and other indicators of psychological and physical health in patients with cancer.
- Trial name
- RESTORE (NCT05227898)
- Testing
- Device: Attune™, Device: Cerena™
- Where
- United States
- Volunteers
- 352 people
- Sponsor
- Blue Note Therapeutics
Endometrial Serous Adenocarcinoma, Stage I Uterine Corpus Cancer
Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer
This research study is studying biomarkers in blood and tissue samples from patients with uterine cancer. Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes…
- Conditions
- Endometrial Serous Adenocarcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer
- Trial name
- NCT01344837
- Testing
- Diagnostic Laboratory Biomarker Analysis, Immunohistochemistry Staining Method, Medical Chart Review
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- Gynecologic Oncology Group
Endometrial Neoplasms
POLE-END REAL LIFE: Endometrial Cancer Early Stages I-II and Advanced Stages III and IV Evaluation of POLE as a Prognostic Factor. Participants Are Women >= 18 Years Old, With the Pole Mutation
POLE-END is a non-profit, observational, retrospective and prospective study which aims to analyze the clinical course of patients with POLE-mutated endometrial cancer with evaluation of Recurrence-Free Survival (RFS), defined as…
- Trial name
- POLE-END (NCT06409039)
- Where
- 2 sites in Italy
- Volunteers
- 80 people
- Sponsor
- Azienda Ulss 2 Marca Trevigiana
Endometrial Cancer
Thunderbeat Technology vs Standard Bipolar Electro-surgery in Total Laparoscopic Hysterectomy With Pelvic Lymphadenectomy for Endometrial Cancer
This prospective randomized pilot study is aimed to verify if the operative time of a TLH with pelvic lymphadenectomy for endometrial cancer FIGO stage IB-II could be reduced using Thunderbeat (an ultrasonic energy device that…
- Trial name
- Thunder Endom (NCT01717794)
- Testing
- Thunderbeat technology, Standard bipolar electrosurgery
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- Catholic University of the Sacred Heart
Cervical Cancer, Endometrial Cancer
Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer
- Trial name
- NCT00287885
- Testing
- docetaxel
- Volunteers
- 18 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Gastric Cancer, Bladder Cancer
Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies
The purpose of the study is to determine to evaluate safety and tolerability of CPL304110 when administered once daily to adults with advanced solid malignancies.
- Conditions
- Gastric Cancer, Bladder Cancer, Squamous Non-small Cell Lung Cancer, Cholangiocarcinoma
- Trial name
- NCT04149691
- Testing
- CPL304110
- Where
- 7 sites in Poland
- Volunteers
- 37 people
- Sponsor
- Celon Pharma SA
Endometrial Cancer Stage I
Programmed Death-1(PD-1) Inhibitor Combined With Progesterone Treatment in Endometrial Cancer
We want to make a comparison of PD-1 inhibitor combined with progesterone versus progesterone alone in the treatment of early stage endometrial cancer patients who want to preserve fertility.
- Trial name
- ECCT (NCT04046185)
- Testing
- PD-1 inhibitor combined progesterone, progesterone
- Volunteers
- 60 people
- Sponsor
- Shanghai First Maternity and Infant Hospital